A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients – the ELDERS study

A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients – the ELDERS study

Older cancer patients are underrepresented in the pivotal trials of checkpoint inhibitors (CPIs). This study aimed to investigate the impact of an ageing immune system on CPI-related toxicity and provide evidence for the role of geriatric assessments with CPI. The ELDERS study is a prospective obser...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:ESMO open 2021-02, Vol.6 (1), p.100042-100042, Article 100042
Hauptverfasser: Gomes, F., Lorigan, P., Woolley, S., Foden, P., Burns, K., Yorke, J., Blackhall, F.
Format: Artikel
Sprache:eng
Schlagworte:
cancer
elderly
ELDERS
immunotherapy
Life Sciences & Biomedicine
Oncology
Original Research
Science & Technology
toxicity
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Older cancer patients are underrepresented in the pivotal trials of checkpoint inhibitors (CPIs). This study aimed to investigate the impact of an ageing immune system on CPI-related toxicity and provide evidence for the role of geriatric assessments with CPI. The ELDERS study is a prospective observational study with two cohorts: older (70+ years of age) and younger (
ISSN:2059-7029
2059-7029
DOI:10.1016/j.esmoop.2020.100042